DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Tocilizumab for Relapsing Polychondritis

Information source: McMaster Children's Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Relapsing Polychondritis

Intervention: Tocilizumab (Drug)

Phase: Phase 2

Status: Withdrawn

Sponsored by: McMaster Children's Hospital

Official(s) and/or principal investigator(s):
Maggie Larché, MD, PhD, Principal Investigator, Affiliation: McMaster University and Children's Hospital

Summary

This is a study for one patient with severe relapsing polychondritis which has been unresponsive to other more conventional medications including prednisone, methotrexate, anakinra and TNF inhibitors. Tolerability, and efficacy of the drug, Tocilizumab will be monitored by clinical assessment and bloodwork.

Clinical Details

Official title: Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Efficacy of Tocilizumab

Secondary outcome: Safety of Tocilizumab

Eligibility

Minimum age: 12 Years. Maximum age: 15 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- A single patient with unremitting inflammatory relapsing polychondritis

Exclusion Criteria:

- As this is a study in a single patient, there are no exclusions

Locations and Contacts

McMaster Children's Hospital, Hamilton, Ontario L8N 3YZ, Canada
Additional Information

Starting date: May 2010
Last updated: May 12, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017